Health
Alnylam Defends Heart Disease Drugs Amid AstraZeneca Trial Failure
Following the failure of AstraZeneca’s heart disease trial, Alnylam is defending its own drugs. The company faces mounting pressure as a result.
Coverage timeline — 1 article
STAT News
An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
2026-08-30 17:29 UTC